KH658

KH658 is an adeno-associated virus (AAV) vector-based gene therapy developed for the treatment of neovascular (wet) age-related macular degeneration (nAMD). It is administered via suprachoroidal space injection and is designed to deliver a gene encoding a therapeutic protein that targets and blocks vascular endothelial growth factor (VEGF), thereby inhibiting abnormal blood vessel growth in the retina. The therapy aims to provide long-term, stable expression of anti-VEGF protein with a single administration, potentially reducing treatment burden and maintaining vision in patients with nAMD. Clinical trials are ongoing in China, with Phase 1/2 studies evaluating safety, tolerability, and efficacy compared to standard intravitreal anti-VEGF therapies[1][2][3][4][5][7].

Other names

KH 658KH658KH-658